Patents by Inventor Kelly Lee Schmeichel
Kelly Lee Schmeichel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11859187Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: GrantFiled: June 24, 2021Date of Patent: January 2, 2024Assignee: The Procter & Gamble CompanyInventors: Juan Esteban Velasquez, Spencer Christopher Rupard, Amy Violet Trejo, Adam Michael Pitz, Kelly Lee Schmeichel, Erin Nicole Swigart, Gregory Allen Penner
-
Publication number: 20230340495Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: ApplicationFiled: December 14, 2022Publication date: October 26, 2023Inventors: Juan Esteban VELASQUEZ, Spencer Christopher RUPARD, Amy Violet TREJO, Adam Michael PITZ, Kelly Lee SCHMEICHEL, Erin Nicole SWIGART, Gregory Allen PENNER, HILDA ANDAMICHE NAMANJA-MAGLIANO, Matthew Scott Wagner
-
Publication number: 20230313201Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: ApplicationFiled: December 14, 2022Publication date: October 5, 2023Inventors: Juan Esteban VELASQUEZ, Spencer Christopher RUPARD, Amy Violet TREJO, Adam Michael PITZ, Kelly Lee SCHMEICHEL, Erin Nicole SWIGART, Gregory Allen PENNER, HILDA ANDAMICHE NAMANJA-MAGLIANO, Matthew Scott Wagner
-
Publication number: 20230287434Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: ApplicationFiled: December 14, 2022Publication date: September 14, 2023Inventors: Juan Esteban VELASQUEZ, Spencer Christopher RUPARD, Amy Violet TREJO, Adam Michael PITZ, Kelly Lee SCHMEICHEL, Erin Nicole SWIGART, Gregory Allen PENNER, HILDA ANDAMICHE NAMANJA-MAGLIANO, Matthew Scott Wagner
-
Publication number: 20230287433Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: ApplicationFiled: December 14, 2022Publication date: September 14, 2023Inventors: Juan Esteban VELASQUEZ, Spencer Christopher RUPARD, Amy Violet TREJO, Adam Michael PITZ, Kelly Lee SCHMEICHEL, Erin Nicole SWIGART, Gregory Allen PENNER, HILDA ANDAMICHE NAMANJA-MAGLIANO, Matthew Scott Wagner
-
Publication number: 20210403919Abstract: An aptamer composition is disclosed which has one or more oligonucleotides that include at least one of deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, or mixtures thereof. The aptamer composition has a binding affinity for one or more cellular membrane glycoproteins selected from the group consisting of: intercellular adhesion molecule 1 (ICAM-1), low-density lipoprotein receptor (LDLR) family members, and cadherin-related family member 3 (CDHR3), preferably intercellular adhesion molecule 1 (ICAM-1), and is configured to reduce the binding of one or more human rhinoviruses to the intercellular adhesion molecule 1 (ICAM-1).Type: ApplicationFiled: June 24, 2021Publication date: December 30, 2021Inventors: Juan Esteban Velasquez, Spencer Christopher Rupard, Amy Violet Trejo, Adam Michael Pitz, Kelly Lee Schmeichel, Erin Nicole Swigart, Gregory Allen Penner
-
Publication number: 20210353562Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives.Type: ApplicationFiled: August 2, 2021Publication date: November 18, 2021Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Patent number: 11083697Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.Type: GrantFiled: August 23, 2018Date of Patent: August 10, 2021Assignee: The Procter & Gamble CompanyInventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Patent number: 11077074Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.Type: GrantFiled: June 19, 2018Date of Patent: August 3, 2021Assignee: The Procter & Gamble CompanyInventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Patent number: 10772848Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes. Also disclosed are methods of treating respiratory illness through administration of a composition comprising phenylephrine, its free and addition salt forms, and mixtures thereof alone, or in combination with other pharmaceutical actives, wherein the composition has a pH of from about 2 to about 5 and is substantially free of aldehydes.Type: GrantFiled: August 23, 2018Date of Patent: September 15, 2020Assignee: The Procter & Gamble CompanyInventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Publication number: 20180360781Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Publication number: 20180360779Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Publication number: 20180360778Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Publication number: 20180360780Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.Type: ApplicationFiled: August 23, 2018Publication date: December 20, 2018Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Publication number: 20180338933Abstract: Disclosed are compositions including phenylephrine, its free and addition salt forms, and mixtures thereof, alone, or in combination with other pharmaceutical actives. The compositions have a pH of about 2 to about 5 and are substantially free of aldehydes.Type: ApplicationFiled: June 19, 2018Publication date: November 29, 2018Inventors: Kelly Lee Schmeichel, Jayant Eknath Khanolkar, Douglas William Gledhill, Susan Elaine Criss, Niranjan Ramji, Elaine Rose Costeines
-
Patent number: 10130557Abstract: A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.Type: GrantFiled: July 28, 2017Date of Patent: November 20, 2018Assignee: The Procter & Gamble CompanyInventors: Kurt Franklin Trombley, Karen Lai-Ting Chan, Isabelle Lafosse-Marin, Jay Robert Morosey, Jr., Karla Mishell Sanchez, Kelly Lee Schmeichel
-
Publication number: 20170319435Abstract: A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.Type: ApplicationFiled: July 28, 2017Publication date: November 9, 2017Inventors: Kurt Franklin Trombley, Karen Lai-Ting Chan, Isabelle Lafosse-Marin, Jay Robert Morosey, JR., Karla Mishell Sanchez, Kelly Lee Schmeichel
-
Patent number: 9744100Abstract: A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.Type: GrantFiled: August 2, 2016Date of Patent: August 29, 2017Assignee: The Procter & Gamble CompanyInventors: Kurt Franklin Trombley, Karen Lai-Ting Chan, Isabelle Lafosse-Marin, Jay Robert Morosey, Jr., Karla Mishell Sanchez, Kelly Lee Schmeichel
-
Publication number: 20170087056Abstract: A blister card with a back side and a front side opposite the back side. The front side has a plurality of blisters and each blister contains a unit dose and each unit dose contains an active. Each blister card contains from about 12 hours to about 24 hours of unit doses according to the dosage instructions. The actives can be the same or different.Type: ApplicationFiled: November 17, 2016Publication date: March 30, 2017Inventors: Rosa Manuela Leon Alonso, Kelly Lee Schmeichel, Isabelle La Fosse-Marin, Angela Jane Deutsch, Thomas Alfred Inglin, Kurt Franklin Trombley, Diane Danheiser Powers, Eduardo De Abreu Mangione, Craig Andrew Hawkins, Jay Robert Morosey, JR.
-
Publication number: 20160374899Abstract: A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.Type: ApplicationFiled: August 2, 2016Publication date: December 29, 2016Inventors: Kurt Franklin Trombley, Karen Lai-Ting Chan, Isabelle Lafosse-Marin, Jay Robert Morosey, JR., Karla Mishell Sanchez, Kelly Lee Schmeichel